Close
CDMO Safety Testing 2026
Novotech

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.
- Advertisement -

Thermo Fisher Scientific, the world leader in serving science announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan.

This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies. As a leading service provider to the cell and gene therapy community, Fisher BioServices is uniquely positioned with the experience, resources, and global expertise to support its customers on their path towards commercialization.

The facility in Tokyo was expanded to include cryogenic storage and logistics by utilizing a combination of proven components and validated procedures developed with years of experience in the cell and gene therapy business. The new modules within this facility allow Fisher BioServices to configure and replicate each site to meet the specific requirements of individual clinical trials with minimal variation, regardless of volume or geographic location. The facility is also supported by a global comprehensive and integrated Quality System based on regulatory requirements, industry best practices and trained personnel.

โ€œJapan is an increasingly important market for cell and gene therapy companies conducting clinical trials,โ€ said Dennis Barger, Fisher BioServices vice president and general manager. โ€œThe addition of cryogenic services to this facility in Japan, combined with our existing capabilities in Europe and the US, enables us to seamlessly support our customersโ€™ global trials as they develop and commercialize their therapies.โ€

About Thermo Fisher Scientificย 
Thermo Fisher Scientific Inc is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands โ€“ Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services โ€“ we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com

Contact:

Thermo Fisher Scientific
Marcia K. Goff, +1-508-902-7041
marcia.goff@thermofisher.com

ย 

Latest stories

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป